The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...
[NEW YORK, SciDev.Net] An international study published in the Malaria Journal claims that a widely used test for detecting ...
Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
In what experts are calling a breakthrough in the global fight against malaria, a new next-generation drug candidate — GanLum ...
An experimental drug was effective against malaria in a new study, potentially offering a much-needed buffer against the ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Zacks Investment Research on MSN
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
Novartis NVS reported positive top-line data from a late-stage study of its investigational new malaria treatment candidate, ...
The fight against Myanmar’s military government has exposed shopkeeper-turned-rebel Moe Gyi to many dangers, including being shot in the back by a drone. He has faced another less evident but ...
Developed by British drugmaker GSK, RTS,S/AS01E in 2021 became the first malaria vaccine to be recommended by the World ...
Abstract: Malaria is a major health threat caused by Plasmod-ium parasites that infect the red blood cells. Two predominant types of Plasmodium parasites are Plasmodium vivax (P. vivax) and Plasmodium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback